A Drug‐Drug Interaction Study to Evaluate the Effect of TAS‐303 on CYP3A Activity in the Small Intestine and Liver

TAS‐303 (4‐piperidinyl 2,2‐diphenyl‐2‐[propoxy‐1,1,2,2,3,3,3‐d(7)] acetate hydrochloride) is a novel selective noradrenaline reuptake inhibitor being developed for the treatment of stress urinary incontinence. An in vitro study and a physiologically based pharmacokinetic model simulation showed that...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumagai, Yuji, Fujita, Tomoe, Maeda, Mika, Sasaki, Yoshinobu, Nagaoka, Makoto, Huang, Jinhong, Takenaka, Toru, Kawai, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318569/
https://www.ncbi.nlm.nih.gov/pubmed/32026490
http://dx.doi.org/10.1002/jcph.1583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318569/
https://www.ncbi.nlm.nih.gov/pubmed/32026490
http://dx.doi.org/10.1002/jcph.1583

Ejemplares similares